Kezar Life Sciences, Inc.
KZR
$6.28
$0.040.64%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -27.85% | -- | |||
| Gross Profit | 27.85% | -- | |||
| SG&A Expenses | -4.29% | -7.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.07% | -17.19% | |||
| Operating Income | 16.07% | 17.19% | |||
| Income Before Tax | 18.08% | 17.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.08% | 17.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.08% | 17.23% | |||
| EBIT | 16.07% | 17.19% | |||
| EBITDA | 16.23% | 17.39% | |||
| EPS Basic | 18.21% | 17.29% | |||
| Normalized Basic EPS | 18.21% | 17.29% | |||
| EPS Diluted | 18.21% | 17.29% | |||
| Normalized Diluted EPS | 18.21% | 17.29% | |||
| Average Basic Shares Outstanding | 0.17% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||